Literature DB >> 34363742

Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody.

Jiwei Huang1, Yueming Wang1, Haoran Zhang2, Xiaoyi Hu3, Ping Wang4, Wen Cai5, Yichu Yuan5, Hao Zeng2, Jin Zhang1, Wen Kong1, Yiran Huang1, Shuo Wang4, Jianming Guo3, Qiang Wei2, Wei Xue1.   

Abstract

Entities:  

Year:  2021        PMID： 34363742     DOI： 10.1002/cac2.12206

Source DB:  PubMed          Journal:  Cancer Commun (Lond)        ISSN： 2523-3548


× No keyword cloud information.
  2 in total

1.  Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy.

Authors:  Kang Ning; Zhen Li; Huiming Liu; Xi Tian; Jun Wang; Yi Wu; Longbin Xiong; Xiangpeng Zou; Yulu Peng; Zhaohui Zhou; Fangjian Zhou; Chunping Yu; Junhang Luo; Hailiang Zhang; Pei Dong; Zhiling Zhang
Journal:  Nutrients       Date:  2022-08-18       Impact factor: 6.706

Review 2.  The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy.

Authors:  Lu Wen; Fan Tong; Ruiguang Zhang; Lingjuan Chen; Yu Huang; Xiaorong Dong
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.